Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

American Journal of Psychiatry

Volumn 153, Issue 12, 1996, Pages 1579-1584

  VanderZwaag, Carol ^a   McGee, Mark ^a   McEvoy, Joseph P ^a   Freudenreich, Oliver ^a   Wilson, William H ^a   Cooper, Thomas B ^a  

^a John Umstead Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ARTICLE; CAPILLARY GAS CHROMATOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SOMNOLENCE; TREATMENT OUTCOME;

EID: 0029903903     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.12.1579     Document Type: Article

References (16)

1. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13:383-390
2. Perry PJ, Miller DD, Arndt SV, Cadoret RJ: Clozapine and nonclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148:231-235; correction: 148:1427
3. Potkin SG, Bera R, Gulaskaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B, Telford J, Plon I., Plon H, Park L, Chang J-J, Oldroyd J, Cooper T: Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55(Sept suppl B): 133-136
4. Kronig MH, Munne RH, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA: Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152:179-182
5. Simpson GM, Cooper TB: Clozapine plasma levels and convulsions. Am J Psychiatry 1978; 135:99-100
6. Freudenreich O, McEvoy JP, Cooper TB: Monitoring of clozapine blood levels in the real world. J Clin Psychopharmacol 1996; 16:90-91
7. Woerner MG, Mennuzza S, Kane JM: Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988; 24: 112-117
8. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1981
9. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48:739-745
10. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammil K, Carter M, Munetz MR, Perel J: Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995; 52:29-41
11. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
12. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia; crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
13. Jann MW, Grimsley SR, Gray EC, Chang W-H: Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24:161-176
14. Choc MG, Lehr RG, Hsuan F, Honigfeld G, Smith HT, Borison R, Volovka J: Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 1987; 4:402-405
15. Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45:79-91
16. Fleischhacker WW, Hummer M, Kurz M, Kurzthaler I, Lieberman JA, Pollack S, Safferman AZ, Kane JM: Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994; 55(Sept suppl 3):78-81